Outcome

The study illustrates the significant neuroprotective effects of hyperbaric oxygen (HBO) therapy on traumatic brain injury (TBI) in mice. Administered at 2.0 absolute atmosphere (ATA) with 100% oxygen HBO therapy was shown to boost both serum and cerebral levels of the anti-inflammatory protein Interleukin-10 (IL-10). This increase in IL-10 was associated with a reduction in lesion volume and cerebral edema as well as improved motor and cognitive functions.

Introduction

Traumatic brain injury (TBI) is a major cause of morbidity and mortality worldwide often leading to long-term neurological deficits. Current treatment options are limited thus necessitating novel therapeutic approaches. This study investigates the neuroprotective effects of hyperbaric oxygen therapy (HBO) on TBI in mice with a particular focus on the role of Interleukin-10 (IL-10) an anti-inflammatory cytokine. HBO treatment administered at 2.0 absolute atmosphere (ATA) for 1 hour using 100% oxygen was found to elevate IL-10 levels in both serum and brain tissue. The therapy significantly reduced lesion volume cerebral edema and notably improved motor and cognitive functions. HBO also mitigated apoptosis and inflammation and enhanced the integrity of the blood-brain barrier by upregulating tight junction proteins. Importantly IL-10 deficiency negated these therapeutic benefits highlighting IL-10’s vital role in the efficacy of HBO. This study suggests that HBO could be a promising treatment for TBI by leveraging IL-10 to augment neuroprotective effects.

Results

The study revealed that Hyperbaric Oxygen Therapy (HBO) administered at 2.0 absolute atmosphere (ATA) for one hour had significant neuroprotective effects on mice with traumatic brain injury (TBI). HBO treatment elevated both serum and cerebral levels of Interleukin-10 (IL-10) an anti-inflammatory cytokine which correlated with multiple protective outcomes against TBI.

Central to the findings HBO therapy notably reduced lesion volume and cerebral edema which were coupled with marked improvements in neurological functions including motor and cognitive abilities. The therapy achieved these effects partly by inhibiting apoptosis; evidenced by decreased levels of cleaved caspase-3 (C3) and Bax expression and increased bcl-2 expression a protein known for its anti-apoptotic properties.

In terms of inflammation HBO substantially reduced the expression of inflammatory markers such as IL-1β IL-6 macrophage inflammatory protein-2 (MIP-2) and monocyte chemoattractant protein-1 (MCP-1). Additionally the activity of matrix metalloproteinase-9 (MMP9) an enzyme associated with inflammation and blood-brain barrier disruption was also decreased.

Further HBO treatment enhanced the blood-brain barrier’s integrity by upregulating tight junction proteins including zonula occludens-1 (ZO-1) and claudin-5.

Crucially the absence of IL-10 in deficient mice abolished the beneficial effects of HBO worsening TBI-induced brain damage and nullifying improvements in neuroinflammation apoptosis and edema reduction. However IL-10 deficiency alone did not significantly alter brain water content or the neurological status of the mice.

Overall the study underscored IL-10’s vital role in mediating the neuroprotective effects of HBO therapy which holds promise as a potential treatment for mitigating TBI-induced damage.

Conclusion

In summary this study underscores the significant neuroprotective effects of hyperbaric oxygen therapy (HBO) in the context of traumatic brain injury (TBI) in mice with a pivotal role attributed to Interleukin-10 (IL-10). HBO treatment at 2.0 ATA for one hour considerably enhanced IL-10 levels which was associated with reductions in lesion volume cerebral edema and improvements in motor and cognitive functions. The therapy also inhibited apoptosis reduced inflammation and strengthened the blood-brain barrier integrity. Crucially the absence of IL-10 negated these benefits highlighting its essential role in the efficacy of HBO. These findings reveal the therapeutic potential of HBO in managing TBI through IL-10-mediated pathways suggesting fruitful avenues for future research to further explore and optimize this treatment approach.